AGEN Agenus Inc.

3.04
+0.07  (+2%)
Previous Close 2.97
Open 2.99
Price To Book -2.64
Market Cap 417,430,988
Shares 137,312,825
Volume 1,194,442
Short Ratio
Av. Daily Volume 869,883

NewsSee all news

  1. VBI Vaccines Announces Phase 2a Clinical Evaluation of VBI-1901 Cancer Vaccine Candidate in Combination with GSK's AS01B Adjuvant System in Recurrent Glioblastoma Patients

    - VBI is the first biopharma company to collaborate with GSK to assess AS01B adjuvant system as part of a therapeutic cancer vaccine candidate - Combination will be tested in additional study arm in Part B of VBI's

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1/2 data due 2019.
AGEN2034 and AGEN1884
Solid tumors
Phase 1 data due 2019.
AGEN1884 (anti-CTLA-4)
Solid cancers
Approval announced October 20, 2017.
Shingrix
Shingles
Phase 1 data presented at ESMO October 2018 noted clinical benefit of 3/7 cervical cancer patients.
AGEN2034 (anti-PD-1)
Cervical cancer
Phase 1 data due 2019.
AGEN1181 - 2nd gen CTLA
Advanced cancer

Latest News

  1. VBI Vaccines Announces Phase 2a Clinical Evaluation of VBI-1901 Cancer Vaccine Candidate in Combination with GSK's AS01B Adjuvant System in Recurrent Glioblastoma Patients

    - VBI is the first biopharma company to collaborate with GSK to assess AS01B adjuvant system as part of a therapeutic cancer vaccine candidate - Combination will be tested in additional study arm in Part B of VBI's